Subvenções e apoios para entidades sociais

PREMIO DE LA CÁTEDRA CSN/UP SEGURIDAD NUCLEAR Y PROTECCIÓN RADIOLÓGICA AL MEJOR TRABAJO FIN DE GRADO DEL CURSO ACADÉMICO 2025/2026

OTROS - UNIVERSITAT POLITÈCNICA DE VALÈNCIA ·

Educación

Período: 20/4/2026 – —

PREMIO DE LA CÁTEDRA CSN/UP SEGURIDAD NUCLEAR Y PROTECCIÓN RADIOLÓGICA A LA MEJOR TESIS DOCTORAL DEL CURSO ACADÉMICO 2025/2026

OTROS - UNIVERSITAT POLITÈCNICA DE VALÈNCIA ·

Educación

Período: 20/4/2026 – —

CONVOCATORIA SUBVENCIONES PARA ALUMNOS CICLOS FORMATIVOS IMPARTIDOS EN LA ESCUELA DE ARTE Y DISEÑO (EMAD), CURSO 2025-26 Y CURSO 2026-27

LOCAL - GARRIGA, LA - AYUNTAMIENTO DE GARRIGA, LA ·

Educación

Período: 16/2/2026 – —

DoW Melanoma Research Program Idea Award

Estados Unidos · US

Quem pode candidatar-se Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Idea Award supports innovative, exploratory, high-risk/potentially high-reward research. Novelty and innovation are expected to be key aspects of the proposed project. By the end of the Idea Award funding period, the anticipated outcomes of successful efforts should establish proof of principle and obtain preliminary data to secure follow-on funding. Distinctive Features: • Preliminary data are discouraged. • After submitting the required pre-application, investigators must receive an invitation to submit a full application.

DoW Melanoma Research Program Team Science Award

Estados Unidos · US

Quem pode candidatar-se Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Team Science Award supports a broad range of hypothesis-driven, multidisciplinary studies that have a short-term goal of advancing the state of the science in melanoma research and/or patient care. Team science is a synergistic effort that harnesses techniques, approaches and perspectives from multiple disciplines and/or therapeutic areas to address complex, multi-dimensional problems that will impact patient outcomes. Distinctive Features: · This funding mechanism requires multiple Principal Investigators (PIs). At least two and up to three PIs should partner to jointly design and execute a single research project ; multi-institutional partnerships are encouraged. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). · Consumer Collaboration Option: Investigators are encouraged, but not required, to form collaborative relationships with the melanoma consumer community to maximize the impact and translatability of the research for the benefit of the intended community(ies). · After submitting the required pre-application, investigators must receive an invitation to submit a full application . Only the Initiating PI will submit a pre-application. All PIs must submit full applications. The Partnering PI(s)’s application is an abbreviated package specific to their proposed research effort.

DoW Melanoma Research Program Melanoma Academy Scholar Award

Estados Unidos · US

Quem pode candidatar-se Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: Supports the addition of independent, early career investigators (Scholars) who are no more than seven years from their initial faculty appointment to the Melanoma Research Program (MRP) Melanoma Academy. The Melanoma Academy is a unique, interactive virtual academy focused on bringing together established investigators and Scholars to develop a network of successful, highly productive melanoma researchers in a collaborative research and career development environment. Distinctive Features: This award mechanism focuses on both the Scholar’s research and career potential in the melanoma field. Scholars must designate a Career Guide. The Career Guide must have a track record of successful mentorship coupled with a strong record of funding and publications in melanoma. Preliminary data are not required.

DoW Melanoma Research Program Survivorship Research Award

Estados Unidos · US

Quem pode candidatar-se Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Survivorship Research Award addresses the relatively new and underfunded area of melanoma-specific survivorship by supporting a broad range of innovative and impactful research that has the intended outcome of improving the health and well-being of melanoma survivors, their families and/or their care partners in the near term. Proposed studies focusing exclusively on animal models or considering survival only without consideration of quality of life, overall health and/or function are not responsive to this funding opportunity. Distinctive Features: · The application must include at least one melanoma consumer collaborator , defined as a melanoma survivor, family member and/or care partner who can provide lived experience expertise to the research project team, or a melanoma-community supporting organization to support the planning, execution, and implementation of the proposed research. · Clinical trials are allowed.

DoW Melanoma Research Program Focused Program Award – Rare Melanomas

Estados Unidos · US

Quem pode candidatar-se Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Focused Program Award – Rare Melanomas, supports a multidisciplinary research program of at least two, but not more than three, distinct but complementary research projects addressing an overarching question relevant to rare melanomas. Distinctive Features: · *Updated for FY26* Investigators must include at least one rare melanoma survivor or patient advocate as part of the project team who will provide advice and consultation throughout planning, implementation, and results dissemination to maximize research impact. · This is a partnering mechanism, requiring an Initiating Principal Investigator (PI) and at least one, but not more than two, Partnering PIs, see Figure 1 . Each named PI is expected to be a Project Leader for one of the proposed research projects. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). · After submitting the required pre-application, investigators must receive an invitation to submit a full application . Only the Initiating PI will submit a pre-application. All PIs must submit full applications. The Partnering PI(s)’s application is an abbreviated package specific to their proposed research project. · Clinical trials are allowed.

Validação de Ensaio de Marcadores de Alta Qualidade para Estudos Clínicos em Câncer (Ensaios Clínicos UH3 Não Permitidos)

Estados Unidos · US

Quem pode candidatar-se Public housing authorities/Indian housing authorities · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Small businesses · State governments · Native American tribal governments (Federally recognized) · County governments · Native American tribal organizations (other than Federally recognized tribal governments) · Public and State controlled institutions of higher education · For profit organizations other than small businesses · Private institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · City or township governments · Independent school districts · Special district governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education

Através desta Notificação de Oportunidade de Financiamento (NOFO), o National Cancer Institute (NCI) pretende acelerar a adoção e validação de marcadores moleculares/celulares/de imagem (referidos como "marcadores" ou "biomarcadores") e ensaios para detecção, diagnóstico, prognóstico, monitoramento e previsão de resposta ou resistência ao tratamento do câncer, bem como marcadores para prevenção e controle do câncer. Esta NOFO também apoiará a validação de marcadores farmacodinâmicos e marcadores de toxicidade. Os candidatos a esta NOFO devem ter um(s) ensaio(s) cujo desempenho tenha sido analiticamente validado em espécimes semelhantes aos do uso clínico pretendido do(s) marcador(es) e ensaio(s). À medida que as quimioterapias e/ou radioterapias são cada vez mais combinadas com imunoterapias para aumentar a durabilidade das respostas anticâncer, ensaios para medir múltiplos marcadores, incluindo marcadores imunológicos, podem ser desenvolvidos e validados simultaneamente. O mecanismo UH3 apoiará a validação clínica de ensaios estabelecidos por até 3 anos usando espécimes de ensaios ou estudos clínicos retrospectivos ou prospectivos. Esta NOFO pode ser usada para validar ensaios existentes para uso em outros ensaios, estudos observacionais ou estudos populacionais. Esforços para harmonizar testes laboratoriais clínicos, incluindo investigação sobre o desempenho e reprodutibilidade de ensaios em vários laboratórios clínicos, também são apropriados para esta oportunidade de financiamento. Os projetos propostos para esta NOFO exigirão multidisciplinaridade…

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Public housing authorities/Indian housing authorities · Native American tribal organizations (other than Federally recognized tribal governments) · City or township governments · Independent school districts · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal governments (Federally recognized) · For profit organizations other than small businesses · County governments · Special district governments · Small businesses · Private institutions of higher education · State governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Public and State controlled institutions of higher education

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this NOFO supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this NOFO supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientist.

Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se Independent school districts · Special district governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Small businesses · Private institutions of higher education · For profit organizations other than small businesses · Native American tribal organizations (other than Federally recognized tribal governments) · County governments · State governments · Public and State controlled institutions of higher education · City or township governments · Native American tribal governments (Federally recognized) · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Public housing authorities/Indian housing authorities

Through this Notice of Funding Opportunity (NOFO) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this NOFO is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" r "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer control and prevention. Research applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this NOFO encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

Innovative Programs to Enhance Research Training (IPERT) (R25 Independent Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal governments (Federally recognized) · Small businesses · Independent school districts · Special district governments · City or township governments · Public housing authorities/Indian housing authorities · State governments · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Public and State controlled institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · For profit organizations other than small businesses · Private institutions of higher education · County governments

NIGMS will support innovative educational activities designed to equip participants with technical, operational, or professional skills required for careers in the biomedical research workforce. Activities must be open to the broader biomedical research community and may focus on participants at one or more career stages from undergraduates to professionals (for example faculty, staff scientists). Funded programs will have a robust program leadership structure, participant recruitment plan, and evaluation and dissemination plans.

NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)

Estados Unidos · US

Quem pode candidatar-se Public and State controlled institutions of higher education · City or township governments · Native American tribal governments (Federally recognized) · Public housing authorities/Indian housing authorities · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · State governments · Private institutions of higher education · Small businesses · For profit organizations other than small businesses · County governments · Independent school districts · Special district governments

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO (PAR-23-286).

NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se Public and State controlled institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Independent school districts · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · Private institutions of higher education · Native American tribal governments (Federally recognized) · Special district governments · Public housing authorities/Indian housing authorities · For profit organizations other than small businesses · State governments · Small businesses · Others (see text field entitled "Additional Information on Eligibility" for clarification) · City or township governments

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFOs (PAR-23-287 or PAR-23-288).

Research Experiences for Teachers (RET) in Engineering and Computer Science

Estados Unidos · US

Quem pode candidatar-se Others (see text field entitled "Additional Information on Eligibility" for clarification)

The Research Experiences for Teachers (RET) in Engineering and Computer Science program supports authentic summer research experiences for K-14 educators to foster long-term collaborations between universities, community colleges, school districts, and industry partners. With this solicitation, the Directorates for Engineering (ENG) and Computer and Information Science and Engineering (CISE) focus on a reciprocal exchange of expertise between K-14 educators and research faculty and (when applicable) industry mentors. K-14 educators will enhance their scientific disciplinary knowledge in engineering or computer science and translate their research experiences into classroom activities and curricula to broaden their students’ awareness of and participation in computing and engineering pathways. At the same time, the hosting research faculty will deepen their understanding of classroom practices, current curricula, pedagogy, and K-14 educational environments.

Mathematical Biology

Estados Unidos · US

Quem pode candidatar-se Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

The Mathematical Biology Program supports research in all areas of mathematical sciences with relevance to the biological sciences. Successful proposals must demonstrate mathematical innovation, biological relevance and significance, and strong integration between mathematics and biology. Some projects of interest to the Mathematical Biology Program may include development of mathematical theories, methodologies, and tools traditionally seen in other disciplinary programs within the Division of Mathematical Sciences. In general, if a proposal is appropriate for review by more than one NSF program, it is advisable to contact the program officers handling each program to determine when and where the proposal should be submitted and to facilitate the review process. The Mathematical Biology Program regularly seeks joint reviews of proposals with programs in the Directorates of Biological Sciences and other relevant programs. Investigators are encouraged to discuss their project with program officers in relevant areas to determine whether it could be considered by more than one program. Research in Undergraduate Institutions (RUI) Investigators submitting an RUI proposal should read the RUI solicitation (link below), as the rules for proposal format may deviate from the Proposal & Award Policies & Procedures Guide (PAPPG). EAGER and RAPID Proposals Prior to submitting proposals for EArly-concept Grants for Exploratory Research (EAGER) or Rapid Response Research (RAPID), Investigators must contact the cognizant program directors. Requests for Award Supplements Principal Investigatorsare encouraged to contact the cognizant program director prior to submission of a proposal for an award supplement. See the PAPPG for more information. Conferences Investigators should carefully read the program solicitation, "Conferences and Workshops in the Mathematical Sciences," (link below) to obtain important information regarding the substance of proposals for conferences, workshops, summer/winter schools, and similar activities. To facilitate timely notification of the availability of support: proposals for conferences, workshops, etc., to be held in the US must be submitted 8 months in advance of the conference date; proposals to support group travel to meetings outside the US must be submitted 12 months in advance of the meeting date.

Resolución rectoral por la que se convocan becas de movilidad de la Escuela Internacional de Doctorado (EIDO) para estudiantes de programas de doctorado en la Universidad de Vigo en el curso académico 2025/2026

OTROS - UNIVERSIDAD DE VIGO ·

Educación

Período: 30/7/2026 – —

Fomento de la actividad cultural en el medio rural de Navarra

AUTONOMICA - COMUNIDAD FORAL DE NAVARRA - DEPARTAMENTO DE CULTURA, DEPORTE Y TURISMO ·

Cultura

Período: 15/9/2026 – —

bases reguladoras de la convocatoria pública de subvenciones para alumnos de preescolar, educación infantil, primaria, secundaria obligatoria, bachiller y ciclos formativos de grado medio correspondiente al curso 2026-2027

LOCAL - MURO - AYUNTAMIENTO DE MURO ·

Educación

Período: 22/7/2026 – —

CONVOCATORIA SUBVENCIONES PROGRAMAS Y ACTIVIDADES DEPORTIVAS CLUBES Y FEDERACIONES 2026

LOCAL - DIPUTACIÓN PROV. DE CUENCA - DIPUTACIÓN PROVINCIAL DE CUENCA ·

Educación

Período: 27/7/2026 – —

Convocatoria de la subvención para estudios no obligatorios año 2025-2026

LOCAL - SANT MARTÍ VELL - AYUNTAMIENTO DE SANT MARTÍ VELL ·

Educación

Período: 27/7/2026 – —

Bases reguladoras y convocatoria de 2026 de las subvenciones para la adecuación de viviendas deshabitadas y el incremento de la oferta de viviendas en alquiler a precio asequible.

LOCAL - AZPEITIA - AYUNTAMIENTO DE AZPEITIA ·

Otras Prestaciones económicas

Subvenciones del programa de ayudas para deportistas individuales "Embajadores del deporte en Sant Salvador de Guardiola"

LOCAL - SANT SALVADOR DE GUARDIOLA - AYUNTAMIENTO DE SANT SALVADOR DE GUARDIOLA ·

Otras Prestaciones económicas

Período: 1/10/2026 – —

Convocatoria ayudas en materia educativa curso 2026-2027 Ayuntamiento de Algímia d'Alfara (Decreto nº 305 de 09/07/2026)

LOCAL - ALGIMIA DE ALFARA - AYUNTAMIENTO DE ALGÍMIA D'ALFARA ·

Educación

Período: 1/9/2026 – —